Congress passed the Corporate Transparency Act (CTA) as an anti-money-laundering initiative in 2021. Absent an applicable exemption,[1] the CTA requires all entities formed or registered to do business in the US (reporting companies) to

Continue Reading Federal court finds the Corporate Transparency Act unconstitutional: Is compliance still required?

On February 23, 2024, the US Treasury Department’s Office of Foreign Assets Control (OFAC), in conjunction with the US State Department, added over 500 entities and individuals to the Specially Designated Nationals and Blocked Persons

Continue Reading New US sanctions target Russia and Russian sanctions evaders in financial, technology, defense, energy, and other sectors

On February 13, 2024, the US Department of the Treasury’s Financial Crimes Enforcement Network (FinCEN) announced a Notice of Proposed Rulemaking (NPRM). This would, for the first time, require SEC-Registered Investment Advisers (RIAs) and Exempt

Continue Reading Treasury proposes new anti-money laundering rule for investment advisers: Top points

On January 21, 2024, the FDA issued a final rule amending its Quality System (QS) regulations under 21 CFR Part 820, which addresses current good manufacturing practice (CGMP) requirements for medical device manufacturers. The amendments

Continue Reading FDA’s new Quality Management System Regulation is here: Key takeaways for device companies in US, EU, and China